Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Member of the Duke Cancer Institute
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994


Hamilton, Erika, Gretchen Kimmick, Judith Hopkins, P Kelly Marcom, Gloria Rocha, Renee Welch, Gloria Broadwater, and Kimberly Blackwell. “Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer..” Clin Breast Cancer 13, no. 6 (December 2013): 416–20.

Full Text

Gucalp, Ayca, Sara Tolaney, Steven J. Isakoff, James N. Ingle, Minetta C. Liu, Lisa A. Carey, Kimberly Blackwell, et al. “Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer..” Clin Cancer Res 19, no. 19 (October 1, 2013): 5505–12.

Full Text

Jones, Lee W., Diane R. Fels, Miranda West, Jason D. Allen, Gloria Broadwater, William T. Barry, Lee G. Wilke, et al. “Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy..” Cancer Prev Res (Phila) 6, no. 9 (September 2013): 925–37.

Full Text

Hamilton, Erika P., and Kimberly L. Blackwell. “How can we optimize treatment of HER2-positive metastatic breast cancer?.” Oncology (Williston Park) 27, no. 3 (March 2013): 180–82.


Hamilton, E. P., and K. L. Blackwell. “How can we optimize treatment of HER2-positive metastatic breast cancer?.” Oncology (Williston Park, N.Y.) 27, no. 3 (March 1, 2013).


Blackwell, K. L. “An option after pertuzumab and TDM-1.” Oncology Report, no. AUG (January 1, 2013).


Cristofanilli, Massimo, Stephen R. D. Johnston, Alexey Manikhas, Henry L. Gomez, Oleg Gladkov, Zhimin Shao, Sufia Safina, et al. “A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer..” Breast Cancer Res Treat 137, no. 2 (January 2013): 471–82.

Full Text

Hamilton, E., K. Blackwell, A. C. Hobeika, T. M. Clay, G. Broadwater, X. R. Ren, W. Chen, et al. “Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion..” J Transl Med, 2013.

Full Text

Cristofanilli, M., S. R. D. Johnston, A. Manikhas, H. L. Gomez, O. Gladkov, Z. Shao, S. Safina, et al. “A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.” Breast Cancer Research and Treatment 137, no. 2 (2013): 471–82.

Full Text

Verma, Sunil, David Miles, Luca Gianni, Ian E. Krop, Manfred Welslau, José Baselga, Mark Pegram, et al. “Trastuzumab emtansine for HER2-positive advanced breast cancer..” N Engl J Med 367, no. 19 (November 8, 2012): 1783–91.

Full Text